WO2000040229B1 - Synergistic tumorcidal response induced by histamine - Google Patents
Synergistic tumorcidal response induced by histamineInfo
- Publication number
- WO2000040229B1 WO2000040229B1 PCT/US2000/000094 US0000094W WO0040229B1 WO 2000040229 B1 WO2000040229 B1 WO 2000040229B1 US 0000094 W US0000094 W US 0000094W WO 0040229 B1 WO0040229 B1 WO 0040229B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- histamine
- administering
- cancer therapy
- antibody
- administration
- Prior art date
Links
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 title claims abstract 28
- 229960001340 histamine Drugs 0.000 title claims abstract 14
- 230000004044 response Effects 0.000 title claims 4
- 230000002476 tumorcidal Effects 0.000 title claims 2
- 230000002195 synergetic Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 claims abstract 20
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 15
- 230000002708 enhancing Effects 0.000 claims abstract 5
- 230000028996 humoral immune response Effects 0.000 claims abstract 3
- 238000001356 surgical procedure Methods 0.000 claims abstract 3
- 102000004965 antibodies Human genes 0.000 claims 7
- 108090001123 antibodies Proteins 0.000 claims 7
- 230000002285 radioactive Effects 0.000 claims 6
- 230000035693 Fab Effects 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 102000005614 monoclonal antibodies Human genes 0.000 claims 4
- 108010045030 monoclonal antibodies Proteins 0.000 claims 4
- 210000004027 cells Anatomy 0.000 claims 3
- 239000000941 radioactive substance Substances 0.000 claims 3
- 229960005486 vaccines Drugs 0.000 claims 3
- 210000004369 Blood Anatomy 0.000 claims 2
- 238000009175 antibody therapy Methods 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000038129 antigens Human genes 0.000 claims 2
- 108091007172 antigens Proteins 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 239000007943 implant Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 102000000543 Histamine receptors Human genes 0.000 claims 1
- 108010002059 Histamine receptors Proteins 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 231100000765 Toxin Toxicity 0.000 claims 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 claims 1
- 229960001727 Tretinoin Drugs 0.000 claims 1
- 230000002009 allergen Effects 0.000 claims 1
- 230000003190 augmentative Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000000039 congener Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229960001660 histamine phosphate Drugs 0.000 claims 1
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrugs Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229930002330 retinoic acid Natural products 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 210000004881 tumor cells Anatomy 0.000 claims 1
- 230000003612 virological Effects 0.000 claims 1
- 235000020942 vitamer Nutrition 0.000 claims 1
- 239000011608 vitamer Substances 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
Abstract
The present invention relates to methods of treating cancer in which histamine is administered in conjunction with other cancer therapies. The cancer therapy includes surgery, radiation, immunotherapy, the administration of an agent which enhances the humoral immune response of the patient or any combination thereof.
Claims
1. A method of augmenting a cancer therapy comprising: administering to a subject a pharmaceutically acceptable form of histamine over a period of time such that a blood histamine concentration sufficient to augment the cancer therapy is achieved; and administering to the subject a cancer therapy, wherein the cancer therapy is selected from the group consisting of surgery, radiation, antibody therapy and administration of an agent which enhances the humoral response of the subject.
2. The method of Claim 1, wherein the pharmaceutically acceptable form of histamine is selected from the group consisting of histamine, histamiπe dihydrochloride, histamine phosphate, histamiπe salts, esters, congeners, prodrugs, histamine receptor agonists and diphenyleπeiodonium.
3. The method of Claim 1, wherein the cancer therapy is radiation therapy selected from the group consisting of external beam radiation, radionuciides, radioactive implants, radioactive antibodies, radioactive lipids, radioactive proteins, radioactive giycolipids and radioactive glycoproteins.
4. The method of Claim 1, wherein the cancer therapy is antibody therapy selected from the group consisting of a monoclonal antibody, a humanized monoclonal antibody, an Fab, an (Fab')2, an Fv, an antibody conjugate, an Fab conjugate, an (Fab')2 conjugate, an Fv conjugate and an antibody heteroconjugate.
5. The method of Claim 1, wherein the cancer therapy is administration of an agent which enhances the humoral response of the subject selected from the group consisting of viral antigens, cancer cell antigens, inactivated cancer cells, vaccines and vitamers.
6. The method of Claim 1 further comprising maintaining the stable blood histamine concentration during the administration of the cancer therapy to the subject.
7. The method of Claim 1, wherein the histamine is administered to the subject indirectly by administering a substance which induces the release of endogenous histamine.
8. The method of Claim 7, wherein the substance is selected from the group consisting of retinoic acid, a retinoid, IL-3 or an ingestible allergen.
9. The method of Claim 1, wherein the administration of histamiπe is performed prior to administering the cancer therapy.
10. The method of Claim 1, wherein the administration of histamine is performed after administering the cancer therapy.
11. The method of Claim 1, wherein the administration of histamine is performed during administration of the cancer therapy.
12. The method of Claim 1, wherein the administration of histamine further comprises administering histamine in a dose from 0.1 to 10.0 milligrams per day.
-16-
13. A method of screening cancer treatments comprising: providing a non-human mammal; grafting human tumor cells into the non-human mammal; administering histamine to the non-human mammal; administering a cancer therapy to the non-human mammal, wherein the cancer therapy is selected from the group consisting of administering a radioactive substance, administering an antibody, administering an agent that enhances the humoral immune response of the non-human mammal, radiation, and surgery; and detecting the tumorcidal response of the non-human mammal.
14. The method of Claim 13, wherein the antibody is a monoclonal antibody.
15. The method of Claim 14, wherein the monoclonal antibody is conjugated to a compound selected from the group consisting of a toxin, a radioactive substance, a radionuclide, an antibody fragment or a second antibody.
16. The method of Claim 13, wherein the agent that enhances the humoral immune response of the non-human mammal is a vaccine.
17. The method of Claim 16, wherein the vaccine comprises a killed cancer cell.
18. The method of Claim 13, wherein the radioactive substance comprises a seed implant.
19. The method of Claim 13, wherein the radiation comprises external beam radiation.
-17-
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00911556A EP1140290A2 (en) | 1999-01-06 | 2000-01-04 | Synergistic tumorcidal response induced by histamine |
| KR1020017008517A KR20010101379A (en) | 1999-01-06 | 2000-01-04 | Synergistic tumorcidal response induced by histamine |
| JP2000591986A JP2002534378A (en) | 1999-01-06 | 2000-01-04 | Synergistic tumoricidal response induced by histamine |
| CA002358754A CA2358754A1 (en) | 1999-01-06 | 2000-01-04 | Synergistic tumorcidal response induced by histamine |
| IL14377200A IL143772A0 (en) | 1999-01-06 | 2000-01-04 | Synergistic tumorcidal response induced by histamine |
| AU33435/00A AU768868B2 (en) | 1999-01-06 | 2000-01-04 | Synergistic tumorcidal response induced by histamine |
| HK02101636.6A HK1040204A1 (en) | 1999-01-06 | 2002-03-04 | Synergistic tumorcidal response induced by histamine |
| AU2004201486A AU2004201486A1 (en) | 1999-01-06 | 2004-04-07 | Synergistic tumorcidal response induced by histamine |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/226,226 US6498181B1 (en) | 1999-01-06 | 1999-01-06 | Synergistic tumorcidal response induced by histamine |
| US09/226,226 | 1999-01-06 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2000040229A2 WO2000040229A2 (en) | 2000-07-13 |
| WO2000040229A3 WO2000040229A3 (en) | 2001-07-19 |
| WO2000040229B1 true WO2000040229B1 (en) | 2001-08-23 |
Family
ID=22848072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2000/000094 WO2000040229A2 (en) | 1999-01-06 | 2000-01-04 | Synergistic tumorcidal response induced by histamine |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US6498181B1 (en) |
| EP (1) | EP1140290A2 (en) |
| JP (1) | JP2002534378A (en) |
| KR (1) | KR20010101379A (en) |
| CN (1) | CN1342096A (en) |
| AU (2) | AU768868B2 (en) |
| CA (1) | CA2358754A1 (en) |
| HK (1) | HK1040204A1 (en) |
| IL (1) | IL143772A0 (en) |
| WO (1) | WO2000040229A2 (en) |
| ZA (1) | ZA200104997B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
| US6498181B1 (en) * | 1999-01-06 | 2002-12-24 | Maxim Pharmaceuticals | Synergistic tumorcidal response induced by histamine |
| PL200134B1 (en) | 1999-05-07 | 2008-12-31 | Genentech Inc | Treatment of autoimmunologic diseases with antagonists binding to cell surface markers |
| WO2001003734A1 (en) * | 1999-07-12 | 2001-01-18 | Genentech, Inc. | Blocking immune response to a foreign antigen using an antagonist which binds to cd20 |
| JP2003505348A (en) * | 1999-07-16 | 2003-02-12 | マキシム ファーマシューティカルス，インコーポレイテッド | Activation and protection of cytotoxic lymphocytes using reactive oxygen metabolite inhibitors |
| US6949243B1 (en) * | 1999-11-24 | 2005-09-27 | Schering Corporation | Methods of inhibiting metastasis |
| US7534417B2 (en) * | 2000-02-24 | 2009-05-19 | Agensys, Inc. | 103P2D6: tissue specific protein highly expressed in various cancers |
| CU22979A1 (en) * | 2000-12-08 | 2004-09-09 | Centro Inmunologia Molecular | IMMUNOTHERAPEUTIC COMBINATION FOR THE TREATMENT OF TUMORS OVER-EXPRESSING RECEPTORS WITH KINASE ACTIVITY IN TYPOSINE WASTE |
| ES2299692T3 (en) * | 2002-04-02 | 2008-06-01 | Nerviano Medical Sciences S.R.L. | COMBINED THERAPY AGAINST TUMORS THAT INCLUDE DERIVATIVES OF REPLACED ACRILOIL DISTMYCIN AND RADIOTHERAPY. |
| EP1530474A1 (en) * | 2002-07-19 | 2005-05-18 | Ludwig Institute For Cancer Research | Enhancing the effect of radioimmunotherapy in the treatment of tumors |
| BR112013016107A2 (en) * | 2010-12-22 | 2017-04-04 | Ifom Fond Inst Firc Di Oncologia Molecolare | dimeric molecule, cancer treatment method, pharmaceutical composition and kit for the diagnosis of an upar-mediated pathology or tumor |
| EP3253445A4 (en) | 2015-02-03 | 2018-02-21 | Nibs Neuroscience Technologies Ltd. | Early diagnosis and treatment of alzheimer disease and mild cognitive impairment |
| BR112018016142A2 (en) * | 2016-02-08 | 2019-10-08 | Immune Pharmaceuticals Ltd | Histamine dihydrochloride combinations and their uses |
| WO2019023263A1 (en) * | 2017-07-25 | 2019-01-31 | Immune Pharmaceuticals, Inc. | Methods and compositions for treating tumors comprising a bcr-abl1 gene fusion |
| RU2020116649A (en) | 2017-10-24 | 2021-11-30 | Лунелла Байотек, Инк. | MITOFLAVOSCINS: Targeting Flavin-Containing Enzymes Eliminates Malignant stem cells (CSCS) by inhibiting mitochondrial respiration |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4886665A (en) | 1987-03-11 | 1989-12-12 | Arcopharma Ltd. | Compositions of oats and nettle extracts to be used as a food additive or pharmaceutical preparation in human health care |
| ATE136786T1 (en) | 1989-09-19 | 1996-05-15 | Syntello Inc | ANTI-TUMOR PREPARATION CONTAINING INTERLEUKIN-2 AND HISTAMINE, ANALOGUES THEREOF OR H2 RECEPTOR AGONISTS |
| US5798339A (en) | 1990-12-17 | 1998-08-25 | University Of Manitoba | Treatment method for cancer |
| US5618846A (en) | 1990-12-17 | 1997-04-08 | University Of Manitoba | Treatment method for cancer |
| CN1079908A (en) | 1992-01-26 | 1993-12-29 | 伊姆罗吉制药公司 | Histamine derivatives and as the method for immunomodulator |
| SE513429C2 (en) | 1992-06-03 | 2000-09-11 | Syntello Inc | Preparations for activating natural killer cells, which contain interferon alfa and biogenic amines |
| EP0646019B9 (en) * | 1992-06-09 | 2002-12-18 | Neorx Corporation | Biotin-DOTA conjugates and their use in pretargeting methods |
| US5843979A (en) * | 1993-02-25 | 1998-12-01 | Bristol-Myers Squibb Company | Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity |
| US5432168A (en) | 1993-12-27 | 1995-07-11 | University Of Manitoba | Method of treatment of hormone-unresponsive metastatic prostate cancer |
| US5478211A (en) * | 1994-03-09 | 1995-12-26 | Baxter International Inc. | Ambulatory infusion pump |
| EP0775197A1 (en) | 1994-08-08 | 1997-05-28 | Maxim Pharmaceuticals, Inc. | Enhanced activation of natural killer cells using an nk cell activator and a hydrogen peroxide scavenger or inhibitor |
| GB9416321D0 (en) | 1994-08-12 | 1994-10-05 | Peptide Therapeutics Ltd | Peptides and antibodies and their use in treatment of carcinomas |
| US5780435A (en) | 1995-12-15 | 1998-07-14 | Praecis Pharmaceuticals Incorporated | Methods for treating prostate cancer with LHRH-R antagonists |
| US5961969A (en) | 1996-05-14 | 1999-10-05 | Maxim Pharmaceuticals, Inc. | Stable circulating histamine levels |
| US6498181B1 (en) * | 1999-01-06 | 2002-12-24 | Maxim Pharmaceuticals | Synergistic tumorcidal response induced by histamine |
-
1999
- 1999-01-06 US US09/226,226 patent/US6498181B1/en not_active Expired - Lifetime
-
2000
- 2000-01-04 IL IL14377200A patent/IL143772A0/en unknown
- 2000-01-04 WO PCT/US2000/000094 patent/WO2000040229A2/en not_active Application Discontinuation
- 2000-01-04 KR KR1020017008517A patent/KR20010101379A/en active Search and Examination
- 2000-01-04 JP JP2000591986A patent/JP2002534378A/en active Pending
- 2000-01-04 CA CA002358754A patent/CA2358754A1/en not_active Abandoned
- 2000-01-04 EP EP00911556A patent/EP1140290A2/en not_active Withdrawn
- 2000-01-04 AU AU33435/00A patent/AU768868B2/en not_active Ceased
- 2000-01-04 CN CN00804524A patent/CN1342096A/en active Pending
-
2001
- 2001-06-19 ZA ZA200104997A patent/ZA200104997B/en unknown
-
2002
- 2002-03-04 HK HK02101636.6A patent/HK1040204A1/en unknown
- 2002-08-09 US US10/217,254 patent/US20020193416A1/en not_active Abandoned
-
2004
- 2004-04-07 AU AU2004201486A patent/AU2004201486A1/en not_active Abandoned
- 2004-06-02 US US10/859,802 patent/US20040219153A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2000040229B1 (en) | Synergistic tumorcidal response induced by histamine | |
| AU2009201403B2 (en) | Treatment of intermediate- and high-grade non-Hodgkins lymphoma with anti-CD20 antibody | |
| Notkins et al. | Elevated γ-globulin and increased antibody production in mice infected with lactic dehydrogenase virus | |
| AU2006312013B2 (en) | Concurrent chemotherapy and immunotherapy | |
| SK282017B6 (en) | Vaccines containing a saponin and a sterol, its production method and use | |
| Phillips et al. | Influence of phospholipid composition on antibody responses to liposome encapsulated protein and peptide antigens | |
| RU2681953C2 (en) | Method for upregulating antigen expression | |
| CA2235718A1 (en) | Method of treating rheumatoid arthritis with low dose type ii collagen | |
| US20040219153A1 (en) | Synergistic tumorcidal response induced by histamine | |
| US6063380A (en) | Enhanced immunogenic vaccine | |
| US7112328B2 (en) | Composition for targeted cell treatment | |
| Williams | Antigen localization in lymphopenic states: I. Localization pattern following chronic thoracic duct drainage | |
| MXPA05010804A (en) | Thorium-227 for use in radiotherapy of soft tissue disease. | |
| Kimler et al. | Response of the 9L rat brain tumor to combination treatment with radiation and bleomycin | |
| Ferrer et al. | Prevention of therapeutically induced regression of sarcoma 180 by immunologic enhancement | |
| US5378815A (en) | Process for indirect targeted immunocytolysis | |
| Adams et al. | Radioimmunotherapy of human lymphoma in athymic, nude mice as monitored by 31P nuclear magnetic resonance | |
| WO1997035884A1 (en) | Improved production of antibodies through the use of combinations of antigen and antibody, test kits incorporating said antibodies, and medical uses of said antibodies | |
| Roska et al. | Immune complex disease in guinea pig lungs: elicitation with pigeon serum | |
| WO2010036146A1 (en) | Use of fc fragments of class g immunoglobulin as an antigen for treating rheumatoid arthritis, agent and method of treatment | |
| Gridley et al. | Effects of proton irradiation on radiolabeled monoclonal antibody uptake in human colon tumor xenografts | |
| Ainsworth | Smart Radiotherapy Biomaterials for Image-Guided In-Situ Vaccination in Cancer | |
| Rachman et al. | Influence of the embryo on the distribution of maternal immunoglobulins in the mouse uterus | |
| WO2008060393A2 (en) | The use of materials and external stimuli for synovectomy | |
| WO2001034192A2 (en) | Improved method of immunization |